Tina Brennan

636 total citations
8 papers, 449 citations indexed

About

Tina Brennan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Tina Brennan has authored 8 papers receiving a total of 449 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Tina Brennan's work include Cancer Genomics and Diagnostics (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and IgG4-Related and Inflammatory Diseases (3 papers). Tina Brennan is often cited by papers focused on Cancer Genomics and Diagnostics (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and IgG4-Related and Inflammatory Diseases (3 papers). Tina Brennan collaborates with scholars based in United States and Canada. Tina Brennan's co-authors include Doron Lipson, Geoff Otto, Vincent A. Miller, Philip J. Stephens, Jeffrey S. Ross, Catherine T. Chung, Cheryl M. Coffin, Abha A. Gupta, Scott C. Borinstein and Christine M. Lovly and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Tina Brennan

7 papers receiving 445 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tina Brennan United States	4	206	184	178	174	131	8	449
Enrico Vasquez Italy	12	112 0.5×	147 0.8×	96 0.5×	99 0.6×	185 1.4×	27	544
Weihua Yin China	10	73 0.4×	101 0.5×	72 0.4×	73 0.4×	29 0.2×	25	279
Hosub Park South Korea	9	45 0.2×	129 0.7×	78 0.4×	42 0.2×	52 0.4×	28	290
Öznur Bal Türkiye	12	42 0.2×	175 1.0×	142 0.8×	30 0.2×	108 0.8×	49	380
Erika Hallmen Germany	11	110 0.5×	125 0.7×	330 1.9×	33 0.2×	35 0.3×	23	411
Н. А. Савелов Russia	8	72 0.3×	186 1.0×	284 1.6×	23 0.1×	73 0.6×	22	388
Laura Yébenes Spain	11	48 0.2×	134 0.7×	93 0.5×	29 0.2×	75 0.6×	24	347
Johanna Rische Germany	8	74 0.4×	71 0.4×	231 1.3×	23 0.1×	94 0.7×	8	411
Milica Kontić Serbia	11	84 0.4×	93 0.5×	111 0.6×	21 0.1×	44 0.3×	43	315
Kimberly Fuhrer United States	6	27 0.1×	193 1.0×	139 0.8×	156 0.9×	33 0.3×	8	387

Countries citing papers authored by Tina Brennan

Since Specialization

Citations

This map shows the geographic impact of Tina Brennan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tina Brennan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tina Brennan more than expected).

Fields of papers citing papers by Tina Brennan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tina Brennan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tina Brennan. The network helps show where Tina Brennan may publish in the future.

Co-authorship network of co-authors of Tina Brennan

This figure shows the co-authorship network connecting the top 25 collaborators of Tina Brennan. A scholar is included among the top collaborators of Tina Brennan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tina Brennan. Tina Brennan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Kulkarni, Harshad, Kevin A. Maupin, Tina Brennan, et al.. (2024). First-in-Human Total-Body PET/CT Imaging Using⁸⁹Zr-Labeled MUC5AC Antibody in a Patient with Pancreatic Adenocarcinoma. Journal of Nuclear Medicine. 65(11). 1815–1815.

Fabrizio, David, Daniel S. Lieber, Christine M. Malboeuf, et al.. (2018). Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab. Cancer Research. 78(13_Supplement). 5706–5706. 28 indexed citations

Fabrizio, David, Christine M. Malboeuf, Daniel S. Lieber, et al.. (2017). Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST). Annals of Oncology. 28. v27–v27. 14 indexed citations

Gupta, Abha A., Doron Lipson, Geoff Otto, et al.. (2015). Abstract 497: Understanding oncogenic fusions: Lessons learned from inflammatory myofibroblastic tumor. Cancer Research. 75(15_Supplement). 497–497. 2 indexed citations

Lovly, Christine M., Abha A. Gupta, Doron Lipson, et al.. (2014). Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions. Cancer Discovery. 4(8). 889–895. 303 indexed citations

Lovly, Christine M., Doron Lipson, Geoff Otto, et al.. (2013). Potentially actionable kinase fusions in inflammatory myofibroblastic tumors.. Journal of Clinical Oncology. 31(15_suppl). 10513–10513. 2 indexed citations

Young, Geneva, Kai Wang, Jie He, et al.. (2013). Clinical next‐generation sequencing successfully applied to fine‐needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathology. 121(12). 688–694. 98 indexed citations

Ross, Jeffrey S., Doron Lipson, Christine E. Sheehan, et al.. (2012). Use of next-generation sequencing (NGS) to detect a novel ALK fusion and a high frequency of other actionable alterations in colorectal cancer (CRC).. Journal of Clinical Oncology. 30(15_suppl). 3533–3533. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact